HAEMONETICS CORP (HAE) Stock Overview

Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.

PRIMARY DOCUMENTFiled Jul 28, 2026

Automatically updated from SEC filings

Company and financial overview

This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.

Market cap estimate$4.86BMid cap

Price / sales3.64xLatest reported fiscal year

Price / earnings49.94xLatest reported fiscal year

Net margin7.3%Net income ÷ revenue

Five-year filing history

Financial performance charts

Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.

Revenue$1.3B-2.0% YoY

Net income$97.3M-42.0% YoY

Research coverage

Full Rithvik analysis coming soon

The live data and primary-source filings above update automatically. A full business, catalyst, risk, valuation, and final-view report will appear here after Rithvik completes and publishes the research.

Data updated2026-09-23Completed daily market candle

Coverage typeAutomatic overviewNo editorial score assigned

Source qualityPrimary SEC filingsMarket feeds may be delayed

Disclaimer

This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market and filing data is provided by third-party and public sources and may be delayed, incomplete, or inaccurate. Automatically calculated figures are estimates and have not been manually verified. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.

HAE